乌尔索酸通过减少MRGPRX2-介导的芽细胞脱粒化来减轻伪过敏反应
Ping-Ping Yan1, Ting-Ting Huang1, Si-Yu Liu1
1Department of Pharmacology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, 710061, China.
Immunology letters
|October 12, 2024
概括
乌尔索酸 (UA) 通过抑制巨细胞上的Mas相关G蛋白结合受体X2 (MRGPRX2) 来有效治疗伪过敏反应. 这种天然化合物通过向关键信号通路来减少过敏反应和炎症.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 细胞生物学 细胞生物学
背景情况:
- 与Mas相关的G蛋白结合受体X2 (MRGPRX2) 通过巨细胞激活调解IgE独立的伪过敏反应.
- 乌尔索酸 (UA) 是一种三类,具有抗过敏性质,但其在伪过敏反应中的机制尚不清楚.
研究的目的:
- 研究乌尔索酸 (UA) 对MRGPRX2-介导的伪过敏反应的治疗作用和机制.
- 评估UA对瘤细胞激活,下游信号通路以及体外和体外过敏反应的影响.
主要方法:
- 使用UA和MRGPRX2激动剂 (化合物48/80,物质P) 治疗的LAD2和MRGPRX2-HEK293细胞的体外研究.
- 在系统性过敏反应和被动性皮肤过敏反应的小鼠模型中体内评估UA的疗效.
- 分析流入,脂酶C-γ (PLCγ) 和核因子kappa-B (NF-κB) 通路的激活.
主要成果:
- UA显著降低了由MRGPRX2激动剂诱导的杆细胞脱粒和化学激素的产生.
- 在体内,UA缓解了全身过敏反应和被动皮肤过敏反应的症状.
- 氨基酸对MRGPRX2表现出结合性,减少了细胞内的流入,并抑制了PLCγ和NF-κB信号通路.
结论:
- 乌尔索酸 (UA) 通过抑制巨细胞激活,有效地减轻MRGPRX2-介导的伪过敏反应.
- UA准了PLCγ和NF-κB通路,这表明了一个新的治疗机制.
- 氨酸显示出潜在的治疗药物,用于由MRGPRX2激活驱动的伪过敏状况.
相关概念视频
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
241
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
241
01:19Antiasthma Drugs: Leukotriene Modifiers
249
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
249
02:06Allergic Reactions
27.3K
Overview
27.3K
01:27Allergic Drug Reactions
817
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
817
01:20Asthma: Pathogenesis and Management
363
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
363
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
253
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
253